微創醫療(00853.HK)擬配售6595.8萬股新股份 融資約15.5億港元
格隆匯 6 月 23日丨微創醫療(00853.HK)發佈公告,2020年6月22日,公司(作為發行人)與J.P. Morgan Securities Plc(作為配售代理)訂立配售協議,據此,配售代理同意按悉數包銷基準促使承配人按每股23.50港元的價格承購合共6595.8萬股新股份。
配售股份佔公司現有已發行股本約3.80%及公司經配發及發行配售股份擴大的已發行股本約3.66%。配售價每股23.50港元較6月22日收市價每股24.35港元折讓約3.49%。
配售事項所得款項總額及淨額預計將分別約為15.50億港元及約15.41億港元。公司擬將該等所得款項淨額用作償還集團銀行貸款、為將來潛在業務發展及投資(如有該等機會)提供資金以及用作集團一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.